Liposarcoma, Dedifferentiated
|
0.600 |
Biomarker
|
disease |
BEFREE |
The use of the combination of MDM2, CDK4, p16, and FISH to detect MDM2 amplification is a reliable basis for the diagnosis of DDLPS with meningothelial-like whorls.
|
31782160 |
2020 |
Liposarcoma, Dedifferentiated
|
0.600 |
Biomarker
|
disease |
BEFREE |
To analyze the utility and limitations of ancillary techniques, we studied 11 cases of DDLPS in challenging conditions and 17 cases of nonlipogenic high-grade sarcomas with immunohistochemistry (IHC) for p16, CDK4, and MDM2 and automated dual-color in situ hybridization (DISH) for MDM2 amplification.
|
31145104 |
2020 |
Liposarcoma, Dedifferentiated
|
0.600 |
Biomarker
|
disease |
BEFREE |
Overexpression of DDIT3, along with MDM2 and CDK4, may contribute to the pathogenesis of dedifferentiated liposarcoma by interfering with adipocytic differentiation.
|
30420727 |
2019 |
Liposarcoma, Dedifferentiated
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
These include gene fusions in vascular neoplasms (FOSB, CAMTA1 and TFE3), round cell sarcomas (BCOR, DUX4 and WT1), and fibroblastic/myofibroblastic tumors (STAT6, ALK and Pan-TRK); amplifications in well-differentiated and dedifferentiated liposarcomas (MDM2 and CDK4); and deletions in several aggressive neoplasms (SMARCB1 and SMARCA4).
|
30382607 |
2019 |
Liposarcoma, Dedifferentiated
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
WDL and DDL share similar background genetic aberrations; both are associated with high-level amplifications in the chromosomal 12q13-15 region, which includes the CDK4 and MDM2 cell cycle oncogenes.
|
30852045 |
2019 |
Liposarcoma, Dedifferentiated
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
Our results suggest that the co-overexpression of MDM2 and CDK4, along with multiple genetic factors, increases the tendency for high-grade sarcoma with a DDLPS-like morphology in transformed human BMSCs by accelerating their growth and migration and blocking their adipogenic potential.
|
31160689 |
2019 |
Liposarcoma, Dedifferentiated
|
0.600 |
Biomarker
|
disease |
BEFREE |
These include MDM2 and CDK4 amplification in well-differentiated and dedifferentiated liposarcomas as well as FUS-DDIT3 rearrangements in myxoid liposarcoma.
|
30793229 |
2019 |
Liposarcoma, Dedifferentiated
|
0.600 |
AlteredExpression
|
disease |
BEFREE |
MDM2 and/or CDK4 protein overexpression and gene amplification are beneficial ancillary studies that can help establish the diagnosis of primary breast ALT/WDL and DDL, and effectively rule out the diagnoses of malignant phyllodes tumor and metaplastic breast carcinoma.
|
29372852 |
2018 |
Liposarcoma, Dedifferentiated
|
0.600 |
Biomarker
|
disease |
BEFREE |
We compared sensitivity and specificity of p16 IHC to MDM2 and CDK4 IHC in the differential diagnosis of ALT-WDLPS (n=19) versus benign adipocytic tumors (n=44) and DDLPS (n=18) versus mimicking sarcomas (n=20).
|
27597521 |
2017 |
Liposarcoma, Dedifferentiated
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
Well-differentiated liposarcoma (WDLPS) and dedifferentiated liposarcoma (DDLPS) are closely related tumors commonly characterized by MDM2/CDK4 gene amplification, and lack clinically effective treatment options when inoperable.
|
28099935 |
2017 |
Liposarcoma, Dedifferentiated
|
0.600 |
Biomarker
|
disease |
BEFREE |
Negative MDM2/CDK4 staining in our case argues against the possibility of dedifferentiated liposarcoma and further supports the diagnosis of true PL.
|
27778364 |
2017 |
Liposarcoma, Dedifferentiated
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
MDM2 and CDK4 gene amplification levels, along with JUN amplification and copy alterations at 3q29, can be utilized for predicting outcome in patients with DDLS.
|
29153098 |
2017 |
Liposarcoma, Dedifferentiated
|
0.600 |
Biomarker
|
disease |
BEFREE |
Combined targeting of MDM2 and CDK4 is synergistic in dedifferentiated liposarcomas.
|
28629371 |
2017 |
Liposarcoma, Dedifferentiated
|
0.600 |
AlteredExpression
|
disease |
BEFREE |
Detection of the amplification itself, or the resulting overexpression of the MDM2 and CDK4 genes by genetic and immunohistochemical methods, is a useful ancillary test in the diagnosis of DDL.
|
26509911 |
2017 |
Liposarcoma, Dedifferentiated
|
0.600 |
Biomarker
|
disease |
BEFREE |
Using MLPA, with a cut-off ratio of >2, 36/71 samples (22 atypical lipomatous tumors/well-differentiated liposarcomas, and 14 dedifferentiated liposarcomas) showed MDM2 and CDK4 amplification.
|
25679065 |
2015 |
Liposarcoma, Dedifferentiated
|
0.600 |
Biomarker
|
disease |
BEFREE |
A shorter recurrence-free survival was associated with dedifferentiated liposarcoma (P<0.001), grade 3 (P<0.001), node involvement (P<0.001), distant metastasis (P=0.02), recurrent status (P=0.009), axial location (P=0.001), and with molecular features such as CDK4 (P=0.05) and JUN amplification (P=0.07).
|
26336885 |
2015 |
Liposarcoma, Dedifferentiated
|
0.600 |
Biomarker
|
disease |
BEFREE |
Coexpression of MDM2 and CDK4 distinguishes DDLPS from PLPS.
|
24227706 |
2014 |
Liposarcoma, Dedifferentiated
|
0.600 |
AlteredExpression
|
disease |
BEFREE |
STAT6 protein expression was analyzed by immunohistochemistry in a well-characterized series of 35 previously unpublished cases of dedifferentiated liposarcoma, all with nuclear MDM2 and/or CDK4 expression by immunohistochemistry and/or cytogenetic features of dedifferentiated liposarcoma.
|
24457460 |
2014 |
Liposarcoma, Dedifferentiated
|
0.600 |
AlteredExpression
|
disease |
BEFREE |
High level of CDK4 amplification is a poor prognostic factor in well-differentiated and dedifferentiated liposarcoma.
|
23852861 |
2014 |
Liposarcoma, Dedifferentiated
|
0.600 |
Biomarker
|
disease |
CTD_human |
Treatment with the CDK4 inhibitor PD0332991 was associated with a favorable progression-free rate in patients with CDK4-amplified and RB-expressing WDLS/DDLS who had progressive disease despite systemic therapy.
|
23569312 |
2013 |
Liposarcoma, Dedifferentiated
|
0.600 |
Biomarker
|
disease |
BEFREE |
To identify a possible multicomponent therapy, we performed a combinatorial drug screen in a DDLS-derived cell line and identified cyclin-dependent kinase 4 (CDK4) and insulin-like growth factor 1 receptor (IGF1R) as synergistic drug targets.
|
24065146 |
2013 |
Liposarcoma, Dedifferentiated
|
0.600 |
Therapeutic
|
disease |
CTD_human |
Treatment with the CDK4 inhibitor PD0332991 was associated with a favorable progression-free rate in patients with CDK4-amplified and RB-expressing WDLS/DDLS who had progressive disease despite systemic therapy.
|
23569312 |
2013 |
Liposarcoma, Dedifferentiated
|
0.600 |
AlteredExpression
|
disease |
BEFREE |
Herein, we first comparatively examined the amplification and expression of FRS2 with CDK4 and MDM2 in dedifferentiated liposarcoma (DDLS) and undifferentiated high-grade pleomorphic sarcoma (UHGPS).
|
23393200 |
2013 |
Liposarcoma, Dedifferentiated
|
0.600 |
Biomarker
|
disease |
BEFREE |
The CDKN2A/CDKN2B/CDK4/CCND1 pathway is pivotal in well-differentiated and dedifferentiated liposarcoma oncogenesis: an analysis of 104 tumors.
|
21910158 |
2011 |
Liposarcoma, Dedifferentiated
|
0.600 |
Biomarker
|
disease |
CTD_human |
Finally, we found that short hairpin RNA (shRNA)-based knockdown of several genes amplified in dedifferentiated liposarcoma, including CDK4 and YEATS4, decreased cell proliferation.
|
20601955 |
2010 |